Innocan Pharma Secures Additional Insider Debenture Financing Ahead of Planned U.S. Offering

InnoCan Pharma ( (TSE:INNO) ) has provided an update.

Innocan Pharma plans to issue an additional US$200,000 debenture to its largest shareholder, Tamar Innovest, following a prior US$450,000 debenture earlier in March, with both instruments carrying a 10% annual interest rate and secured under an existing general security agreement in Alberta. The new debenture will mature in 12 months or upon completion of Innocan’s proposed U.S. public offering and is expected to close around April 1, 2026, with proceeds earmarked for working capital and general corporate purposes.

Because Tamar Innovest is an insider managed by director Ralph Bossino and already holds 17% of Innocan’s outstanding shares, the financing is classified as a related-party transaction under MI 61-101, though the company is relying on exemptions from formal valuation and minority approval since the debenture’s value is below 25% of its market capitalization. The deal, approved by independent directors, provides short-term bridge financing that should support Innocan’s operations as it advances its planned U.S. capital markets strategy, while highlighting ongoing backing from a key strategic shareholder.

The most recent analyst rating on (TSE:INNO) stock is a Hold with a C$8.50 price target. To see the full list of analyst forecasts on InnoCan Pharma stock, see the TSE:INNO Stock Forecast page.

Spark’s Take on INNO Stock

According to Spark, TipRanks’ AI Analyst, INNO is a Neutral.

The score is weighed down primarily by weak financial performance (ongoing losses and deteriorating cash flow despite strong gross margins and low leverage). Technicals also remain soft with negative MACD and price below key longer-term moving averages. Valuation is only mildly supportive because the negative P/E reflects lack of profitability and no dividend data is available.

To see Spark’s full report on INNO stock, click here.

More about InnoCan Pharma

Innocan Pharma is an innovator in the pharmaceuticals and wellness sectors, focusing on CBD-based technologies and consumer products. In its pharmaceuticals segment, the company has developed a CBD-loaded liposome drug delivery platform designed to provide precise dosing and prolonged, controlled release of synthetic CBD for non-opioid pain management. In the wellness segment, Innocan offers a broad range of high-performance self-care and beauty products aimed at promoting a healthier lifestyle, primarily marketed through its 60% owned subsidiary BI Sky Global Ltd., which specializes in advanced, targeted online sales.

Average Trading Volume: 1,895

Technical Sentiment Signal: Sell

Current Market Cap: C$29.65M

For detailed information about INNO stock, go to TipRanks’ Stock Analysis page.